Regeneron Pharmaceuticals (NASDAQ:REGN) has announced an anticipated acquired in-process research and development (IPR&D) charge of approximately $24 million for the second quarter of 2024.

This stems from up-front payments and premiums on equity securities arising from recent collaboration and licensing agreements.

The charge is projected to impact both GAAP and non-GAAP net income per diluted share by roughly $0.18 for the quarter.